http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 21 Aug 2026 18:33:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++HARROW%2C+INC.+++++++++++++++++++++++++++Filed+by%3A+Shojaei+Amir/26962675.html si-local-file:///var/storage/secattach/20260821/26962675.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HARROW%2C+INC.+++++++++++++++++++++++++++Filed+by%3A+Shojaei+Amir/26962675.html Fri, 21 Aug 2026 18:33:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++144++++++++HARROW%2C+INC.+++++++++++++++++++++++++++Filed+by%3A+Shojaei+Amir/26962675.html si-local-file:///var/storage/secattach/20260821/26962675.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++HARROW%2C+INC.+++++++++++++++++++++++++++Filed+by%3A+Shojaei+Amir/26962675.html Fri, 21 Aug 2026 18:33:00 -0400 HROW O.03238652 http://www.streetinsider.com/Corporate+News/Harrow+study+shows+Iheezo+cuts+discomfort+after+eye+injections/26952674.html <p>Harrow (Nasdaq: HROW) announced results from an investigator-initiated study showing that its anesthetic product Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% reduced patient-reported discomfort following intravitreal injections compared with proparacaine ophthalmic solution 0.5%.</p><p>The prospective, randomized, contralateral-eye study enrolled 50 adult patients undergoing same-day bilateral intravitreal injections, evaluating 100 eyes across a single private retina practice. Each patient received Iheezo in one randomly assigned eye and proparacaine 0.5% in the fellow eye, with both eyes also receiving 2% lidocaine-soaked pledgets beforehand.</p><p>Patients reported approximately 58% less discomfort overall in the Iheezo-treated eye across all four post-injection assessments, measured on a 0-to-10 numeric rating http://www.streetinsider.com/Corporate+News/Harrow+study+shows+Iheezo+cuts+discomfort+after+eye+injections/26952674.html Thu, 20 Aug 2026 07:04:59 -0400 HROW http://www.streetinsider.com/FDA/Harrow+study+shows+Iheezo+cuts+discomfort+after+eye+injections/26952674.html <p>Harrow (Nasdaq: HROW) announced results from an investigator-initiated study showing that its anesthetic product Iheezo (chloroprocaine hydrochloride ophthalmic gel) 3% reduced patient-reported discomfort following intravitreal injections compared with proparacaine ophthalmic solution 0.5%.</p><p>The prospective, randomized, contralateral-eye study enrolled 50 adult patients undergoing same-day bilateral intravitreal injections, evaluating 100 eyes across a single private retina practice. Each patient received Iheezo in one randomly assigned eye and proparacaine 0.5% in the fellow eye, with both eyes also receiving 2% lidocaine-soaked pledgets beforehand.</p><p>Patients reported approximately 58% less discomfort overall in the Iheezo-treated eye across all four post-injection assessments, measured on a 0-to-10 numeric rating http://www.streetinsider.com/FDA/Harrow+study+shows+Iheezo+cuts+discomfort+after+eye+injections/26952674.html Thu, 20 Aug 2026 07:04:59 -0400 HROW http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Press+Releases/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html <p>NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.</p> <p>Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+IHEEZO%C2%AE+Data+in+Patient-Reported+Discomfort+Following+Intravitreal+Injections/26952600.html Thu, 20 Aug 2026 07:00:00 -0400 A.50204356 HROW O.00063252 O.03238652 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+14++Filed+by%3A+Shojaei+Amir/26939081.html si-local-file:///var/storage/secattach/20260817/26939081.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+14++Filed+by%3A+Shojaei+Amir/26939081.html Mon, 17 Aug 2026 17:48:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+14++Filed+by%3A+Shojaei+Amir/26939081.html si-local-file:///var/storage/secattach/20260817/26939081.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+14++Filed+by%3A+Shojaei+Amir/26939081.html Mon, 17 Aug 2026 17:48:00 -0400 HROW O.03238652 http://www.streetinsider.com/Earnings/Harrow+Health+%28HROW%29+Misses+Q2+EPS+by+35c/26898754.html <p>Harrow Health (NASDAQ: HROW) reported Q2 EPS of ($0.46), $0.35 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $70.7 million versus the consensus estimate of $70.96 million.</p><p>For earnings history and earnings-related data on Harrow Health (HROW) <a href="http://www.streetinsider.com/ec_earnings.php?q=HROW">click here</a>.</p> http://www.streetinsider.com/Earnings/Harrow+Health+%28HROW%29+Misses+Q2+EPS+by+35c/26898754.html Mon, 10 Aug 2026 16:44:47 -0400 HROW http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HARROW%2C+INC.++++++++++++++For%3A+Jun+30/26898396.html si-local-file:///var/storage/secattach/20260810/26898396.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HARROW%2C+INC.++++++++++++++For%3A+Jun+30/26898396.html Mon, 10 Aug 2026 16:28:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HARROW%2C+INC.++++++++++++++For%3A+Jun+30/26898396.html si-local-file:///var/storage/secattach/20260810/26898396.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++HARROW%2C+INC.++++++++++++++For%3A+Jun+30/26898396.html Mon, 10 Aug 2026 16:28:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+10/26897989.html si-local-file:///var/storage/secattach/20260810/26897989.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+10/26897989.html Mon, 10 Aug 2026 16:11:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+10/26897989.html si-local-file:///var/storage/secattach/20260810/26897989.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+10/26897989.html Mon, 10 Aug 2026 16:11:00 -0400 HROW O.03238652 http://www.streetinsider.com/Press+Releases/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html <p align="justify"><strong>Second Quarter 2026 and Selected Highlights: </strong></p> <ul type="disc"><li>Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year</li><li>Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)</li><li>VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growth</li><li>VEVYE secured another coverage win, after gaining expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026</li><li>IHEEZO® delivered quarterly revenue of $15.6 million, and achieved http://www.streetinsider.com/Press+Releases/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html Mon, 10 Aug 2026 16:05:00 -0400 HROW O.03238652 http://www.streetinsider.com/Press+Releases/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html <p align="justify"><strong>Second Quarter 2026 and Selected Highlights: </strong></p> <ul type="disc"><li>Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year</li><li>Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)</li><li>VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growth</li><li>VEVYE secured another coverage win, after gaining expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026</li><li>IHEEZO® delivered quarterly revenue of $15.6 million, and achieved http://www.streetinsider.com/Press+Releases/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html Mon, 10 Aug 2026 16:05:00 -0400 HROW O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html <p align="justify"><strong>Second Quarter 2026 and Selected Highlights: </strong></p> <ul type="disc"><li>Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year</li><li>Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)</li><li>VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growth</li><li>VEVYE secured another coverage win, after gaining expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026</li><li>IHEEZO® delivered quarterly revenue of $15.6 million, and achieved http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html Mon, 10 Aug 2026 16:05:00 -0400 HROW O.03238652 http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html <p align="justify"><strong>Second Quarter 2026 and Selected Highlights: </strong></p> <ul type="disc"><li>Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year</li><li>Reiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)</li><li>VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growth</li><li>VEVYE secured another coverage win, after gaining expanded formulary coverage with a top-three national commercial pharmacy benefit manager effective August 1, 2026</li><li>IHEEZO® delivered quarterly revenue of $15.6 million, and achieved http://www.streetinsider.com/Globe+Newswire/Harrow+Announces+Second+Quarter+2026+Financial+Results/26897714.html Mon, 10 Aug 2026 16:05:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+03/26878661.html si-local-file:///var/storage/secattach/20260806/26878661.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+03/26878661.html Thu, 06 Aug 2026 07:15:00 -0400 HROW O.03238652 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+03/26878661.html si-local-file:///var/storage/secattach/20260806/26878661.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++HARROW%2C+INC.++++++++++++++For%3A+Aug+03/26878661.html Thu, 06 Aug 2026 07:15:00 -0400 HROW O.03238652